Table 3.
The echocardiographic detection of the rats in each group
| Group (n = 5) | LVESD (mm) | LVEDD (mm) | LVEF (%) | LVFS (%) |
|---|---|---|---|---|
| Sham | 3.5 ± 0.3 | 7.5 ± 0.40 | 53.3 ± 4.7 | 89.8 ± 5.5 |
| MI | 9.1 ± 0.6* | 10.9 ± 0.8* | 16.51 ± 3.1* | 54.8 ± 3.1* |
| LTS | 6.5 ± 0.7** | 8.9 ± 0.9** | 35.6 ± 3.6** | 69.7 ± 2.8** |
| HTS | 5.5 ± 0.8** | 8.8 ± 0.4** | 37.5 ± 4.1** | 75.5 ± 3.2** |
| LPS | 10.8 ± 0.5** | 12.1 ± 0.1** | 10.6 ± 1.0** | 28.6 ± 2.01** |
| T + LPS | 5.9 ± 0.3*** | 8.9 ± 0.1*** | 36.9 ± 1.79*** | 72.9 ± 4.87*** |
| LTS + LPS | 8.5 ± 1.2*** | 10.1 ± 0.9*** | 25.4 ± 3.8*** | 59.0 ± 2.9*** |
| HTS + LPS | 7.2 ± 0.9*** | 9.3 ± 1.1*** | 33.3 ± 2.9*** | 62.3 ± 3.3*** |
MI, myocardial infarction; LTS, low‐dose tanshinone IIA; HTS, high‐dose tanshinone IIA; LPS, Lipopolysaccharide; LVESD, left ventricular end‐systole dimension; LVEDD, left ventricular end‐diastole dimension; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening.
* P < .05 compared with the Sham group; **P < .05 compared with the MI group; ***P < .05 compared with the LPS group.